Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved outcomes compared to known outcomes in untreated patients.
- If you got treated early, there was no long-haul.
Will the medical community advise patients to do this?
- It's very unlikely because all early treatments were demonized by the NIH and CDC in order to allow for EUAs to be granted to the vaccine makers.
- So they keep that information from public view and recommend Paxlovid instead (which is not 95% effective and doesn't reduce your rate of long-haul COVID).
Look what the medical community did to Paul Marik
- They fired him for using effective treatments
- The key is to treat people early with repurposed drugs
- In April 2020, shortly after the pandemic started, Marik started the COVID-19 Early Treatment Fund
- No world government was spending any money funding the testing of these early treatment protocols
- He put in $1M of his own money and raised another $5M from mostly private donors
No comments:
Post a Comment